Efficacy and safety of once ‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes

ConclusionsSwitching from exenatide b.i.d. to exenatide q.w. resulted in a reduction in glycated hemoglobin, fasting plasma glucose and the incidence of hypoglycemia, and improvement in β‐cell function and treatment satisfaction in patients with type 2 diabetes. These findings will be useful for selecting optimal treatment in individuals with type 2 diabetes.

Source: Journal of Diabetes Investigation - October 7, 2019 Category: Endocrinology Authors: Yuusuke Watanabe, Yoshifumi Saisho, Jun Inaishi, Kinsei Kou, Akira Yamauchi, Yasuhiko Kanazawa, Yoshiaki Okubo, Mikiya Tokui, Takatoshi Imai, Rie Murakami, Tami Tsuchiya, Hironobu Sasaki, Tatsuhiro Masaoka, Junichiro Irie, Shu Meguro, Hiros Tags: Clinical Trial Source Type: research